You have 9 free searches left this month | for more free features.

Lymphoma, Large B-Cell, Diffuse

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Molecular Classification of Relapsed/Refractory Diffuse Large

Completed
  • Lymphoma, Large B-Cell, Diffuse
  • Gene Expression Profiling
  • Gene expression profile
  • Shanghai, Shanghai, China
    Yian Zhang
Mar 31, 2022

Tumor Heterogeneity in Diffuse Large B-cell Lymphoma in Relation

Recruiting
  • Lymphoma, Large B-Cell, Diffuse
    • Copenhagen, Denmark
      Department of Hematology, Rigshospitalet
    Jan 12, 2022

    Lymphoma, Large B-Cell, Diffuse, Fatigue Trial in Columbus (Fatigue Reduction Diet)

    Completed
    • Lymphoma, Large B-Cell, Diffuse
    • Fatigue
    • Fatigue Reduction Diet
    • Columbus, Ohio
      The Ohio State University
    Apr 26, 2022

    18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma

    Completed
    • Lymphoma, Large B-Cell, Diffuse
    • FDG PET radiomic feature evaluation
    • Hangzhou, Zhejiang, China
      Second Affiliated Hospital, School of Medicine, Zhejiang Univers
    Sep 27, 2021

    Relapsed/Refractory Diffuse Large B Cell Lymphoma Trial in Seoul (Glofitamab, Poseltinib, Lenalidomide)

    Recruiting
    • Relapsed/Refractory Diffuse Large B Cell Lymphoma
    • Glofitamab, Poseltinib, Lenalidomide
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    May 30, 2022

    Lymphoma, Large B-Cell, Diffuse Trial in Saint Louis, Columbus (Brentuximab vedotin, Lenalidomide)

    Completed
    • Lymphoma, Large B-Cell, Diffuse
    • Saint Louis, Missouri
    • +1 more
    Feb 16, 2022

    Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in Boston (Copanlisib, Venetoclax)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +2 more
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    May 4, 2022

    Relapsed Diffuse Large B-cell Lymphoma Trial in Detroit (loncastuximab tesirine)

    Recruiting
    • Relapsed Diffuse Large B-cell Lymphoma
    • loncastuximab tesirine
    • Detroit, Michigan
      Barbara Ann Karmanos Cancer Institute
    Jun 24, 2022

    Diffuse Large B Cell Lymphoma Trial (Rituximab, Cyclophosphamide, Doxorubicin)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • (no location specified)
    Apr 24, 2022

    TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System

    Completed
    • Lymphoma, B-Cell
      • Montpellier, France
        Uh Montpellier
      Nov 12, 2021

      Diffuse Large B Cell Lymphoma Trial in Shanghai (zanubrutinib)

      Recruiting
      • Diffuse Large B Cell Lymphoma
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Mar 13, 2022

      Diffuse Large B Cell Lymphoma, CAR-T, Radiotherapy Trial (ultra-fraction radiotherapy)

      Not yet recruiting
      • Diffuse Large B Cell Lymphoma
      • +3 more
      • ultra-fraction radiotherapy
      • (no location specified)
      Aug 22, 2022

      Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma

      Completed
      • Diffuse Large B-cell Lymphoma (DLBCL)
      • CAR-T
      • Allo-HSCT cohort
      • East Hanover, New Jersey
        Novartis Investigative Site
      Jun 29, 2022

      Lymphoma, B-Cell Trial in San Antonio (Roflumilast)

      Active, not recruiting
      • Lymphoma, B-Cell
      • San Antonio, Texas
        Mays Cancer Center, UT Health San Antonio
      Mar 9, 2022

      Large B-Cell Lymphoma, DLBCL Trial (Tafasitamab, Lenalidomide)

      Not yet recruiting
      • Large B-Cell Lymphoma
      • Diffuse Large B-Cell Lymphoma
      • (no location specified)
      Jun 17, 2022

      Diffuse Large B Cell Lymphoma, CNS Metastasis Trial in Herlev

      Recruiting
      • Diffuse Large B Cell Lymphoma
      • Central Nervous System Metastasis
        • Herlev, Capital Region, Denmark
          Herlev Hopital
        Mar 21, 2022

        Resistance to GNC-038 in Relapsed and Refractory Diffuse Large

        Recruiting
        • Diffuse Large B Cell Lymphoma
          • Shanghai, Shanghai, China
            Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
          Apr 17, 2022

          Diffuse Large B Cell Lymphoma Trial in Wenzhou (Zanubrutinib+Rituximab+Lenalidomide, RCHOP/RCDOP)

          Recruiting
          • Diffuse Large B Cell Lymphoma
          • Wenzhou, Zhejiang, China
            First Affiliated Hospital of Wenzhou Medical University
          Jun 20, 2022

          The Potential of Patient-reported Outcome Measures in Detection

          Recruiting
          • Diffuse Large B Cell Lymphoma
          • Patient Reported Outcome
          • No intervention
          • Copenhagen, Denmark
            Therese Lassen
          Mar 18, 2022

          Relapsed DLBCL, Refractory DLBCL Trial in New York (Ipilimumab, Nivolumab)

          Completed
          • Relapsed Diffuse Large B-Cell Lymphoma
          • Refractory Diffuse Large B-Cell Lymphoma
          • New York, New York
            Icahn School of Medicine at Mount Sinai
          Apr 4, 2022

          Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (Ociperlimab, Tislelizumab,

          Recruiting
          • Relapsed Diffuse Large B-cell Lymphoma
          • Refractory Diffuse Large B-cell Lymphoma
          • Beijing, Beijing, China
            Beijing Cancer Hospital
          May 4, 2022

          Diffuse Large B-cell Lymphoma Trial in Toulouse (Patient with histologically confirmed diffuse large B-cell lymphoma with a

          Recruiting
          • Diffuse Large B-cell Lymphoma
          • Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP.
          • Toulouse, France
            Institut Universitaire du Cancer Toulouse - Oncopole
          Mar 28, 2022

          Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib plus R-ICE, Decitabine plus R-ICE, Chidamide plus R-ICE)

          Not yet recruiting
          • Diffuse Large B Cell Lymphoma
          • Zanubrutinib plus R-ICE
          • +4 more
          • Shanghai, Shanghai, China
            Ruijin Hospital
          Apr 26, 2022

          Diffuse Large B Cell Lymphoma,DLBCL Trial in Chengdu (PM 8.4 mg/m2, PM 11.2 mg/m2)

          Not yet recruiting
          • Diffuse Large B Cell Lymphoma´╝îDLBCL
          • PM 8.4 mg/m2
          • PM 11.2 mg/m2
          • Chengdu, Sichuan, China
            West China Hospital Sichuan University
          Sep 28, 2022

          Predict CNS Involvement in Diffuse Large B-Cell Lymphoma:Danish

          Completed
          • Diffuse Large B Cell Lymphoma
          • +2 more
            • (no location specified)
            Dec 13, 2021